What is the Par Drugs And Chemicals PE ratio today?
Par Drugs And Chemicals' PE ratio is 10.9 at the 29 October 2026 close (₹114.67 a share): a market capitalisation of ₹141 crore divided by consolidated net profit of ₹13 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹13.1 crore) it is 10.8.
What is the Par Drugs And Chemicals net worth?
Par Drugs And Chemicals' net worth — shareholders' equity in its consolidated balance sheet — was ₹119 crore on 30 September 2026, up 12.1% from ₹106 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹141 crore at the 29 October 2026 close.
What is the Par Drugs And Chemicals book value per share?
Par Drugs And Chemicals' book value per share was ₹96.98 on 30 September 2026: shareholders' equity of ₹119 crore divided by the 1.23 crore shares in issue, up 12.1% from ₹86.50 a year earlier. The share price at the 29 October 2026 close was ₹114.67.
What is the Par Drugs And Chemicals PB ratio (price to book value)?
Par Drugs And Chemicals' price-to-book (PB) ratio is 1.18 at the 29 October 2026 close: a market capitalisation of ₹141 crore divided by shareholders' equity (book value) of ₹119 crore on 30 September 2026. That is a book value of ₹96.98 per share against a share price of ₹114.67.
What is the Par Drugs And Chemicals ROE and ROCE?
In FY26, Par Drugs And Chemicals' return on equity (ROE) was 12.4% and its return on capital employed (ROCE) was 12.3%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 14.5% and ROCE 16.5%.
What is the Par Drugs And Chemicals free cash flow?
In FY26, Par Drugs And Chemicals generated ₹16.4 crore of cash from operations and spent ₹2 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹14.5 crore. In FY25 it was ₹14.9 crore.
What is the Par Drugs And Chemicals market cap?
Par Drugs And Chemicals' market capitalisation was ₹141 crore at the 29 October 2026 close: 1.23 crore shares at ₹114.67 each.
Is Par Drugs And Chemicals debt free?
Yes. Par Drugs And Chemicals had no borrowings on 30 September 2026 (consolidated balance sheet), and it held ₹36.4 crore of cash, bank balances and current investments.
What is the Par Drugs And Chemicals EPS?
Par Drugs And Chemicals' basic earnings per share (EPS) were ₹10.65 in FY26, against ₹10.86 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹10.56.
What is the Par Drugs And Chemicals debt to equity ratio?
Par Drugs And Chemicals' debt-to-equity ratio was 0.00 on 30 September 2026: no borrowings against total equity of ₹119 crore. A year earlier, on 30 September 2025, it was 0.00.
What is the Par Drugs And Chemicals promoter holding?
Promoters held 73.41% of Par Drugs And Chemicals on 30 September 2026, unchanged from the previous quarter and up 0.04 percentage points from 73.37% a year earlier, according to the shareholding pattern filed with NSE.
What is the Par Drugs And Chemicals shareholding pattern?
On 30 September 2026, Par Drugs And Chemicals' shares were held by promoters 73.41%, domestic institutions (DII) 0.09% and retail and other non-institutional investors 26.51%.
What are the Par Drugs And Chemicals latest quarterly results?
Par Drugs And Chemicals' latest results are for Q2 FY27 (July–September 2026), filed on 29 October 2026: consolidated net profit ₹2.6 crore, down 36.4% from ₹4.1 crore in Q2 FY26; revenue from operations ₹27.4 crore, down 4.3% year on year.
What is the Par Drugs And Chemicals revenue and profit in FY26?
In FY26 (April 2025–March 2026), Par Drugs And Chemicals' consolidated net profit was ₹13.1 crore, down 1.9% from ₹13.4 crore in FY25, on revenue from operations of ₹104 crore (up 2.7%). Over three years, from FY23, net profit was up 15.7%.
When are the Par Drugs And Chemicals next results?
Par Drugs And Chemicals has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
How does Par Drugs And Chemicals compare with its peers?
On FY26 consolidated figures, against BALAXI PHARMACEUTICALS, Crown Lifters and Steel City Securities: Par Drugs And Chemicals' operating margin of 13.0% is the third highest of the four (BALAXI PHARMACEUTICALS 2.4%, Crown Lifters 34.2%, Steel City Securities 25.4%; peer average 20.6%); its return on equity of 12.4% is the second highest of the four (BALAXI PHARMACEUTICALS 0.6%, Crown Lifters 12.8%, Steel City Securities 10.8%; peer average 8.0%); its revenue growth over three years of 2.7% a year is the third highest of the four (BALAXI PHARMACEUTICALS −7.1% a year, Crown Lifters 27.3% a year, Steel City Securities 4.5% a year; peer average 8.2% a year).
How does the Par Drugs And Chemicals PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Par Drugs And Chemicals' PE ratio is 10.8, the third highest of the four: BALAXI PHARMACEUTICALS 74.6, Crown Lifters 13.6 and Steel City Securities 8.1, a peer average of 32.1. Each is the company's market capitalisation at that price divided by its FY26 net profit.
Par Drugs And Chemicals vs BALAXI PHARMACEUTICALS: how do they compare?
In FY26, Par Drugs And Chemicals earned net profit of ₹13.1 crore on revenue of ₹104 crore, against ₹1.4 crore on ₹270 crore for BALAXI PHARMACEUTICALS. Par Drugs And Chemicals' operating margin was 13.0% (BALAXI PHARMACEUTICALS 2.4%) and its return on equity 12.4% (BALAXI PHARMACEUTICALS 0.6%). At the 29 October 2026 close, Par Drugs And Chemicals' market capitalisation was ₹141 crore against ₹106 crore for BALAXI PHARMACEUTICALS, and its PE ratio on FY26 profit 10.8 against 74.6.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
